Blood Reviews
Volume 23, Issue 1 , Pages 11-23 , January 2009

Recent developments in the treatment of aggressive non-Hodgkin lymphoma

References 

  1. Sandin S, Hjalgrim H, Glimelius B, Rostgaard K, Pukkala E, Askling J. Incidence of non-Hodgkin’s lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiol Biomarkers Prev. 2006;15:1295–1300
  2. Broccia G, Cocco P, Casula P. Incidence of non-Hodgkin’s lymphoma and Hodgkin’s disease in Sardinia, Italy: 1974–1993. Haematologica. 2001;86:58–63
  3. Pollan M, Lopez-Abente G, Moreno C, et al. Rising incidence of non-Hodgkin’s lymphoma in Spain: analysis of period of diagnosis and cohort effects. Cancer Epidemiol Biomarkers Prev. 1998;7:621–625
  4. Morgan G, Vornanen M, Puitinen J, et al. for the Biomed Study Group Changing trends in the incidence of non-Hodgkin’s lymphoma in Europe. Ann Oncol. 1997;8(Suppl. 2):49–54
  5. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592
  6. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481–488
  7. Non-Hodgkin’s Lymphoma Classification Project . A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–3918
  8. Maartense E, Kluin-Nelemans HC, le Cessie S, Kluin PM, Snijder S, Noordijk EM. Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age. Cancer. 2000;89:2667–2676
  9. McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–1493
  10. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. New Engl J Med. 1993;328:1002–1006
  11. Fisher RI, Gaynor ER, Dahlberg S, et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin’s lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-priority Lymphoma Study. Ann Oncol. 1994;5(Suppl. 2):91–95
  12. International Non-Hodgkin’s Lymphoma Prognostic Factors Project . A predictive model for aggressive non-Hodgkin’s lymphoma. New Engl J Med. 1993;329:987–994
  13. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New Engl J Med. 2002;346:235–242
  14. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126
  15. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127
  16. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–5033
  17. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391
  18. Coiffier B, Feugier P, Mounier N, et al. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol. 2007;25(18S):[Abstract 8009]
  19. Jost LM, Kloke O, Stahel RA. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin’s lymphoma. Ann Oncol. 2005;16(Suppl. 1):i58–i59
  20. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626–633
  21. Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14:881–893
  22. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634–641
  23. Pfreundschuh M, Zeynalova S, Duehrsen U, et al. Dose-escalated CHOP plus etoposide (Hi-CHOEP) is not superior to base-line CHOEP in young good-prognosis patients with aggressive lymphoma: results of a randomized DSHNHL trial. J Clin Oncol. 2006;24(18S):[Abstract 7513]
  24. Verdonck LF, Notenboom A, de Jong DD, et al. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood. 2007;109:2759–2766
  25. National Comprehensive Cancer Network. Non-Hodgkin’s lymphomas: the national comprehensive cancer network clinical practice guidelines in oncology, version 1.2007; March 2, 2007. <http://www.nccn.org> [accessed 14.05.07].
  26. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–116
  27. Schubert J, Reiser M, Wenger M, et al. Bi-weekly dosing preserves the efficacy of rituximab in elderly patients with poor-prognosis DLBCL: results from the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study group (DSHNHL). J Clin Oncol. 2006;24;[Abstract 7536]
  28. Poeschel V, Nickelsen M, Hanel M, et al. Dose-dense rituximab in combination with biweekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma(DLBCL): results of a phase-I/II and pharmacokinetic study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2006;108:774a
  29. Reiser M, Wenger M, Nickenig C, Peter N, Metzner B, Pfreundschuh M. Serum levels and pharmacokinetic of rituximab in bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial. J Clin Oncol. 2006;24(18S):[Abstract 7537]
  30. Sonneveld P, van Putten W, Biesma B, et al. Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non-Hodgkin’s lymphoma in elderly patients. Blood. 2006;108;[Abstract 210]
  31. Delarue R, Mournier N, Haioun C, et al. Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP 14 or R-CHOP21: preliminary results of the LNH03-6B randomized GELA study. Blood. 2006;108;[Abstract 2436]
  32. UK Clinical Research Network. A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin’s lymphoma. UKCRN ID 1437.<http://pfsearch.ukcrn.org.uk/StudyDetail.aspx?TopicID=1&StudyID=1437> [accessed 18.06.07].
  33. Bosly A, Bron D, Van Hoof A, et al. for the Lymphoma Dose Project: a National Study Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87:277–283
  34. Lee KW, Kim DY, Yun T, et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer. 2003;98:2651–2656
  35. Lepage E, Gisselbrecht C, Haioun C, et al. for the Groupe d’Etude des Lymphomes de l’Adulte Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: application to LNH-87 protocol. Ann Oncol. 1993;4:651–656
  36. Epelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma: a multivariate analysis including dose intensity variables. Cancer. 1990;66:1124–1129
  37. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963–977
  38. López A, Alonso JD, Gómez-Codina J, et al. Febrile neutropenia in lymphoma patients is associated with substantial resource use and healthcare costs in clinical practice in Spain. Blood. 2006;108;[Abstract 5512]
  39. Pettengell R, Schwenkglenks M, Leonard R et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008 [Epub ahead of print].
  40. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453
  41. Wolf M, Bentley M, Marlton P, et al. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 2006;47:2344–2350
  42. Mey UJ, Maier A, Schmidt-Wolf IG, et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer. 2007;15:877–884
  43. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496–502
  44. Moore TD, Patel T, Segal ML et al. A single pegfilgrastim dose per cycle supports dose-dense (q14d) CHOP-R in patients with non-Hodgkin’s lymphoma. In: Presented at the 2003 annual meeting of the American Society of Hematology, December 7, 2003, San Diego, CA [Poster 2365].
  45. Smith TJC, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205
  46. National Comprehensive Cancer Network. Myeloid growth factors: the national comprehensive cancer network clinical practice guidelines in oncology, version 1.2007; December 8, 2006. <http://www.nccn.org> [accessed 14.05.07.
  47. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973–1997. Bethesda (MD): National Cancer Institute; 2000;
  48. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: a nationwide study. J Clin Oncol. 2004;22:4302–4311
  49. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2:47–56
  50. Repetto L, Biganzoli L, Koehne CH, et al. EORTC cancer in the elderly task force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003;39:2264–2272
  51. Morrison VA, Weller EA, Habermann TM, et al. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP: an intergroup experience (CALGB 9793, ECOG-SWOG 4494). Blood. 2004;104;[Abstract 3309]
  52. Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin’s lymphoma (United States). Cancer Cause Contr. 2006;17:647–654
  53. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007;12:1416–1424
  54. Fayad L, Younes A. Novel treatment strategies for aggressive non-Hodgkin’s lymphoma. Expert Opin Pharmacother. 2006;7:733–748
  55. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867–4874

PII: S0268-960X(08)00050-7

doi: 10.1016/j.blre.2008.05.002

Blood Reviews
Volume 23, Issue 1 , Pages 11-23 , January 2009

Article Tools

* Image Usage & Resolution